ADC Therapeutics (NYSE:ADCT) Hits New 52-Week High on Better-Than-Expected Earnings

Shares of ADC Therapeutics SA (NYSE:ADCT) hit a new 52-week high during mid-day trading on Wednesday after the company announced better than expected quarterly earnings. The company traded as high as $4.95 and last traded at $4.7950, with a volume of 1561459 shares traded. The stock had previously closed at $4.23.

The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.28. The business had revenue of $23.06 million for the quarter, compared to the consensus estimate of $22.29 million.

Key ADC Therapeutics News

Here are the key news stories impacting ADC Therapeutics this week:

• Positive Sentiment: Q4 results beat expectations: Q4 EPS came in better than analyst estimates (reported loss narrower than expected) and revenue of roughly $23.1M topped consensus — a primary near‑term catalyst for the rally. Read More.
• Positive Sentiment: Cash runway and financing flexibility: Company reported ~$261.3M in cash and amended its HealthCare Royalty financing agreement, which management says provides greater strategic flexibility and supports operations into at least 2028. Read More.
• Positive Sentiment: Clear clinical milestones and commercial upside: Management reiterated LOTIS‑5 Phase 3 topline data expected in Q2 2026, with full LOTIS‑5 and LOTIS‑7 data by year‑end 2026, and outlined a $600M–$1B peak revenue target for ZYNLONTA if programs succeed — a meaningful long‑term growth driver. Read More.
• Positive Sentiment: Market reaction: Coverage noted the stock reached a 52‑week high following the earnings beat, reflecting positive investor sentiment and momentum. Read More.
• Neutral Sentiment: Operational disclosure and investor materials: Management hosted a conference call and released the slide deck and transcript; useful for investors wanting detail on commercialization progress and trial designs. Read More.
• Negative Sentiment: Clinical and execution risk remains material: The stock’s upside depends on successful LOTIS‑5/LOTIS‑7 readouts — negative or mixed results would likely reverse recent gains. Read More.
• Negative Sentiment: Company still unprofitable: ADC reported a quarterly loss (albeit smaller than expected); analysts expect continued negative EPS near‑term, so market gains hinge on future revenue ramp and trial success. Read More.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Royal Bank Of Canada reiterated an “outperform” rating and issued a $5.00 price target on shares of ADC Therapeutics in a report on Wednesday, December 3rd. Wall Street Zen upgraded shares of ADC Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ADC Therapeutics in a research note on Wednesday, January 21st. Finally, Guggenheim reiterated a “buy” rating and set a $10.00 target price on shares of ADC Therapeutics in a report on Wednesday, November 12th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $7.33.

Hedge Funds Weigh In On ADC Therapeutics

Several hedge funds have recently made changes to their positions in ADCT. Eventide Asset Management LLC acquired a new stake in shares of ADC Therapeutics in the fourth quarter valued at approximately $11,875,000. Nantahala Capital Management LLC boosted its holdings in ADC Therapeutics by 141.6% during the fourth quarter. Nantahala Capital Management LLC now owns 5,475,433 shares of the company’s stock worth $19,328,000 after purchasing an additional 3,209,144 shares during the last quarter. TCG Crossover Management LLC bought a new position in ADC Therapeutics in the third quarter valued at $5,561,000. Lynx1 Capital Management LP bought a new position in ADC Therapeutics in the third quarter valued at $5,303,000. Finally, Prosight Management LP increased its stake in ADC Therapeutics by 13.5% in the 4th quarter. Prosight Management LP now owns 8,477,338 shares of the company’s stock valued at $29,925,000 after buying an additional 1,005,035 shares during the last quarter. 41.10% of the stock is owned by institutional investors.

ADC Therapeutics Stock Performance

The firm’s 50-day simple moving average is $3.92 and its 200 day simple moving average is $3.88. The stock has a market capitalization of $607.76 million, a P/E ratio of -4.09 and a beta of 1.92.

ADC Therapeutics Company Profile

ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity.

At the core of ADC Therapeutics’ portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S.